Purpose In preclinical models, non-cytotoxic suramin (concentrations< 50 μM) potentiates
the activity of multiple chemotherapeutic agents. The present study evaluated the safety and …

Purpose: Our preclinical studies have shown that acidic and basic fibroblastic growth factors
confer broad spectrum chemoresistance and that low concentrations (10–50 μm) of suramin …

Background The purpose of this study was to evaluate the potential of noncytotoxic doses of
suramin to reverse chemotherapy resistance in advanced chemonaive and chemoresistant …

Purpose We reported that nontoxic suramin treatments enhance the activity of chemotherapy
in preclinical models, a finding supported by the results of subsequent phase I/II trials in …

Purpose We reported that suramin produced chemosensitization at nontoxic doses. This
benefit was lost at the∼ 10-fold higher, maximally tolerated doses (MTD). The aim of the …

P-229 Phase II evaluation of low dose suramin as a modulator of paclitaxel/carboplatin (P/C)
in non-small cell lung cancer (NSCLC) patients × Close The Infona portal uses cookies, ie …

Heading Abstract Purpose. The optimal schedule of administration of suramin has not been
well defined. The purpose of this study was to determine the maximum tolerated dose and …

Suramin inhibits the growth of non-small cell lung cancer (NSCLC) and breast cancer in vitro
by blocking the action of most known growth factors. The clinical efficacy of suramin was …

Purpose: Suramin, a polysulfonated naphthylurea, has been shown to be effective in the
treatment of several cancers. We have reported that suramin, at dose concentrations higher …

PURPOSE We used population pharmacokinetic-parameter estimates and designed a fixed
dosing schedule to maintain plasma suramin concentrations between 100 and 300 …